• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $FATE

    Fate Therapeutics Inc.

    Subscribe to $FATE
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

    IPO Year: 2013

    Exchange: NASDAQ

    Website: fatetherapeutics.com

    Peers

    $CYAD
    $CDTX
    $PSTX
    $SRNE
    $TGTX
    $TPTX

    Recent Analyst Ratings for Fate Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    11/18/2024Underperform → Neutral
    BofA Securities
    6/17/2024$4.00 → $6.00Neutral → Overweight
    Piper Sandler
    3/27/2023$6.00Equal Weight
    Wells Fargo
    1/24/2023$115.00 → $7.00Buy → Neutral
    H.C. Wainwright
    1/6/2023$20.00 → $7.00Outperform → Market Perform
    BMO Capital Markets
    1/6/2023$71.00 → $12.00Overweight → Neutral
    Piper Sandler
    1/6/2023Outperform → Market Perform
    Cowen
    1/6/2023$107.00 → $5.30Buy → Hold
    Stifel
    1/6/2023$42.00 → $7.00Outperform → Neutral
    Wedbush
    1/6/2023$72.00 → $4.00Buy → Underperform
    BofA Securities
    See more ratings

    Fate Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Fate Therapeutics upgraded by BofA Securities

      BofA Securities upgraded Fate Therapeutics from Underperform to Neutral

      11/18/24 3:46:41 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Fate Therapeutics from Neutral to Overweight and set a new price target of $6.00 from $4.00 previously

      6/17/24 7:25:36 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo resumed coverage on Fate Therapeutics with a new price target

      Wells Fargo resumed coverage of Fate Therapeutics with a rating of Equal Weight and set a new price target of $6.00

      3/27/23 8:55:35 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Fate Therapeutics from Buy to Neutral and set a new price target of $7.00 from $115.00 previously

      1/24/23 7:39:57 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Fate Therapeutics from Outperform to Market Perform and set a new price target of $7.00 from $20.00 previously

      1/6/23 8:20:47 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Fate Therapeutics from Overweight to Neutral and set a new price target of $12.00 from $71.00 previously

      1/6/23 8:19:55 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics downgraded by Cowen

      Cowen downgraded Fate Therapeutics from Outperform to Market Perform

      1/6/23 8:18:47 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Fate Therapeutics from Buy to Hold and set a new price target of $5.30 from $107.00 previously

      1/6/23 8:18:47 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics downgraded by Wedbush with a new price target

      Wedbush downgraded Fate Therapeutics from Outperform to Neutral and set a new price target of $7.00 from $42.00 previously

      1/6/23 8:17:50 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Fate Therapeutics from Buy to Underperform and set a new price target of $4.00 from $72.00 previously

      1/6/23 8:17:16 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Fate Therapeutics Inc. SEC Filings

    See more
    • SEC Form DEFA14A filed by Fate Therapeutics Inc.

      DEFA14A - FATE THERAPEUTICS INC (0001434316) (Filer)

      4/17/25 4:07:31 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Fate Therapeutics Inc.

      DEF 14A - FATE THERAPEUTICS INC (0001434316) (Filer)

      4/17/25 4:05:27 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Fate Therapeutics Inc.

      PRE 14A - FATE THERAPEUTICS INC (0001434316) (Filer)

      4/7/25 4:01:23 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Fate Therapeutics Inc.

      10-K - FATE THERAPEUTICS INC (0001434316) (Filer)

      3/5/25 4:03:44 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - FATE THERAPEUTICS INC (0001434316) (Filer)

      3/5/25 4:02:33 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Fate Therapeutics Inc.

      8-K - FATE THERAPEUTICS INC (0001434316) (Filer)

      1/6/25 4:01:28 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Fate Therapeutics Inc.

      SCHEDULE 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      12/26/24 9:00:09 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Fate Therapeutics Inc.

      144 - FATE THERAPEUTICS INC (0001434316) (Subject)

      12/20/24 9:00:14 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - FATE THERAPEUTICS INC (0001434316) (Filer)

      11/29/24 2:33:53 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Fate Therapeutics Inc.

      10-Q - FATE THERAPEUTICS INC (0001434316) (Filer)

      11/12/24 4:03:31 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Fate Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Fate Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2025 the Company granted restricted stock units (RSUs) representing 30,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering in

      5/2/25 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients, today announced that five presentations of clinical and preclinical data from the Company's induced pluripotent stem cell (iPSC) product platform will be featured at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, being held in New Orleans, Louisiana on May 13-17, 2025. The Company has been selected to deliver an oral presentation on the translational data from its Phase 1 clinical trial of FT522, an off-

      4/29/25 9:25:39 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

      –   Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process –   RMAT review by FDA included initial clinical safety and activity data from ongoing Phase 1 study of FT819 in SLE –   Additional Phase 1 clinical data of FT819 to be presented at medical conferences in 2025 SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced that the U.S. Food and Drug Administra

      4/14/25 8:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2025 the Company granted restricted stock units (RSUs) representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees enterin

      4/2/25 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE Completed Type D Meeting with FDA to Enable FT819 Off-the-Shelf CAR T-cell Dose Expansion in Additional B Cell-mediated Autoimmune Diseases First FT819 Off-the-Shelf CAR T-cell Patient Treated without Conditioning Chemotherapy as Add-on to Maintenance Therapy in SLE $307 Million in Cash, Cash Equivalents and Investments with Projected Operating Runway through YE26 SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced

      3/5/25 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on March 3, 2025 the Company granted restricted stock units (RSUs) representing 24,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering in

      3/4/25 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics to Present at Upcoming Investor Conferences

      SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference, including a fireside chat at 1:30 PM ET on Tuesday, February 25, 2025TD Cowen 45th Annual Health Care Conference, including a company presentation at 11:50 AM ET on Monday, March 3, 2025 in Boston, MassachusettsBarclays 27th Annual Global Hea

      2/14/25 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 3, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 35,000 shares of the Company's common stock at an exercise price per share of $1.27, which was the closing price per share of the Company's common stock as reported by NASDAQ on February 3, 2025, the options grant date, and (ii) restricted sto

      2/4/25 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on January 2, 2025 the Company granted (i) non-qualified stock options to two newly-hired non-executive employees to purchase a total of 72,000 shares of the Company's common stock at an exercise price per share of $1.79, which was the closing price per share of the Company's common stock as reported by NASDAQ on January 2, 2025, the options grant date, and (ii) restricted stoc

      1/3/25 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

      All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinica

      12/9/24 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

      First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPS

      5/9/24 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

      SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results and highlight operational updates, including a review of its FT819 and FT522 programs for autoimmune diseases being featured on the same day at the American Society of Gene and Cell Therapy 27th Annual Meeting. In order

      5/6/24 8:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

      CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initiated of FT825 / ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 $316 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FA

      2/26/24 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

      SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Monday, February 26, 2024 at 5:00 PM ET to report its fourth quarter and full year 2023 financial results and provide a corporate update. In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under

      2/15/24 8:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

      Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy IND Application Cleared by FDA for FT825/ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 iPSC-derived CAR T-cell Product Platform Expanded into Autoimmunity; IND Application Cleared by FDA for FT819 CD19-targeted 1XX CAR T-cell Program for Systemic Lupus Erythematosus $350 Million in Cash, Cash Equivalents, and Investments to Support Runway into 2H25 SAN DIEGO, Nov. 08, 2023 (GLOBE N

      11/8/23 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

      SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023 at 5:00 PM ET to report its third quarter 2023 financial results and provide a corporate update. In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Pre

      10/25/23 8:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

      Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy 2H23 IND Submission Planned under ONO Collaboration for FT825/ONO-8250; HER2-targeted CAR T-cell Program Incorporates Seven Novel Synthetic Controls Designed to Overcome Unique Challenges in Treating Solid Tumors Dose Escalation Ongoing in Phase 1 Studies of FT819 CD19-targeted 1XX CAR T-cell Program for B-cell Malignancies and of FT576 BCMA-targeted CAR NK Cell Program for Multiple Myeloma Ended 2Q23 with $385 Million in Cash, Cash Equivalents, and Investments Supporting Runway in

      8/8/23 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

      SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023 at 5:00 PM ET to report its second quarter 2023 financial results and provide a corporate update. In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Pres

      7/28/23 8:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates

      Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large B-cell Lymphoma FT576 BCMA-targeted CAR NK Cell Program Accruing Patients in Multi-dose Escalation Cohorts for Multiple Myeloma; Initial Translational Data Support Potential of Combination Regimen to Induce Differentiated Immune Reconstitution Profile and Extend FT576 Functional Persistence Clinical Initiation of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma Anticipated in 2H23; Preclinical Studies Ongoing to Extend Clinical Reach to Autoimmune Diseases Completed Corp

      5/3/23 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

      SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 3, 2023 at 5:00 PM ET to report its first quarter 2023 financial results and provide a corporate update. In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Present

      4/24/23 8:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Fate Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Fate Therapeutics Announces Leadership Transition

      Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Vala

      11/29/24 1:05:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

      SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced the appointment of Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors effective immediately. Dr. Mozaffarian brings to the Company medical and scientific leadership in the field of immunology and autoimmunity, with over 20 years of research and industry experience in the discovery, development, and commercialization of novel small and large molecule therapeutics. "Dr. Moza

      7/31/24 8:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO

      - Series A led by Frazier Life Sciences, 5AM Ventures and DCVC Bio, bringing total raised to date to $82.5 million - Paul Grayson joins as Chief Executive Officer, bringing additional expertise in business strategy, oncology, and G-protein coupled receptor biology - Radionetics expands board of directors with the appointment of Eric Shiozaki, Ph.D., Partner at DCVC Bio Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing. The round was led by Frazier Life Sciences, 5AM Ventures, and new invest

      1/3/24 7:00:00 AM ET
      $CRNX
      $FATE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer

      SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Brian T. Powl has been appointed Chief Commercial Officer. Mr. Powl brings to Fate Therapeutics extensive commercial leadership experience in hematologic malignancies and solid tumors, having previously served as the Global Commercial CAR T lead at Celgene Corporation where he oversaw the commercial development strategy of the company's CAR T-cell therapies. "We are excited to welcome Brian to Fate Therapeutics as we begin to chart our late-stage clinical developme

      6/30/22 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer

      > Dr. Agarwal is Currently Chairwoman of Onxeo's Board, a Position Held Since June 2021 > Company Outlines Development Strategy Plans Including Preparation for U.S. Pre-IND Meeting for First-in-Class DDR Inhibitor AsiDNA® and Plans for Building Infrastructure in the United States > New Private Financing Expands Onxeo's Runway Into Second Quarter 2023 Regulatory News: Onxeo S.A. (PARIS:ALONX, Nasdaq First North Copenhagen: ONXEO))), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced the appointment of Dr. Shefali Agarwal as President and Chief Executive O

      4/7/22 1:00:00 AM ET
      $FATE
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Appoints Yuan Xu to its Board of Directors

      SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director. Dr. Xu brings to Fate Therapeutics over 25 years of discovery, development, manufacturing, and commercial experience in the global biopharmaceuticals business, most recently serving as the Chief Executive Officer and Board Member of Legend Biotech Corporation where she led the company's efforts in advancing ciltacabtagene autoleucel (cilta-cel) from proof-of-concept in 2018 to BLA pr

      8/4/21 8:00:00 AM ET
      $AKRO
      $FATE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer

      SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chief Technical Officer. Dr. Plavsic brings over 20 years of broad technical excellence in global biopharmaceutical operations, having led teams in the commercial-scale cGMP manufacture and distribution, as well as the clinical-stage process, assay, and formulation development, of complex biologics. As Chief Technical Officer, Mark will oversee the Company's manufacturing, technical, and supply chain operations. "We ar

      6/15/21 8:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service

      SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 years with the Company. Dr. Shoemaker has been with Fate Therapeutics since February 2009, having served as the Company’s Chief Scientific Officer since May 2015. Bob Valamehr, Ph.D., Chief Research and Development Officer of Fate Therapeutics and scientific leader of its iPSC Product Platform since January 2010, w

      3/25/21 7:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Fate Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

      SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      11/14/24 7:50:18 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

      SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      10/25/24 9:37:07 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Fate Therapeutics Inc. (Amendment)

      SC 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      3/25/24 5:15:23 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fate Therapeutics Inc. (Amendment)

      SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      2/13/24 5:04:40 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Fate Therapeutics Inc.

      SC 13G - FATE THERAPEUTICS INC (0001434316) (Subject)

      2/12/24 6:06:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fate Therapeutics Inc. (Amendment)

      SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      2/9/24 6:19:03 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Fate Therapeutics Inc.

      SC 13G - FATE THERAPEUTICS INC (0001434316) (Subject)

      1/25/24 4:19:53 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fate Therapeutics Inc. (Amendment)

      SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      1/24/24 9:46:44 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fate Therapeutics Inc. (Amendment)

      SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      1/22/24 1:46:42 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Fate Therapeutics Inc. (Amendment)

      SC 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      12/28/23 4:53:50 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Fate Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President and CEO Valamehr Bahram

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      1/16/25 6:36:35 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Tahl Cindy was granted 70,000 shares, increasing direct ownership by 21% to 406,707 units (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      1/16/25 6:32:36 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Bressi Jerome Charles was granted 65,000 shares, increasing direct ownership by 24% to 335,203 units (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      1/16/25 6:31:40 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Bressi Jerome Charles sold $9,269 worth of shares (5,980 units at $1.55), decreasing direct ownership by 2% to 270,203 units (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      1/13/25 4:06:16 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Tahl Cindy sold $8,764 worth of shares (5,654 units at $1.55), decreasing direct ownership by 2% to 336,707 units (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      1/13/25 4:05:23 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Valamehr Bahram sold $13,406 worth of shares (8,705 units at $1.54), decreasing direct ownership by 2% to 349,364 units (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      1/13/25 4:04:38 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Redmile Group, Llc sold $573,943 worth of shares (341,633 units at $1.68), bought $668,580 worth of shares (397,964 units at $1.68), disposed of $1,822,692 worth of shares (1,084,936 units at $1.68) and acquired $1,822,692 worth of shares (1,084,936 units at $1.68) (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      12/26/24 9:00:15 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Redmile Group, Llc converted options into 30,110 shares (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      12/16/24 9:00:10 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Bressi Jerome Charles claimed ownership of 276,183 shares (SEC Form 3)

      3 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      8/21/24 4:26:21 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Xu Yuan sold $2,678 worth of shares (633 units at $4.23), decreasing direct ownership by 7% to 8,669 units (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      8/7/24 4:01:01 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Fate Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc sold $573,943 worth of shares (341,633 units at $1.68), bought $668,580 worth of shares (397,964 units at $1.68), disposed of $1,822,692 worth of shares (1,084,936 units at $1.68) and acquired $1,822,692 worth of shares (1,084,936 units at $1.68) (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      12/26/24 9:00:15 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Redmile Group, Llc disposed of $6,157,976 worth of shares (1,655,370 units at $3.72), acquired $6,157,976 worth of shares (1,655,370 units at $3.72) and bought $166,024 worth of shares (44,630 units at $3.72) (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      12/28/23 9:30:16 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care